The American Diabetes Association (ADA) is a U.S.-based nonprofit health organization focused on preventing and curing diabetes and improving the lives of people affected by the disease. It supports patients, caregivers, clinicians, researchers, and policymakers with evidence-based guidance and resources.
The ADA funds and coordinates diabetes research; publishes peer-reviewed journals, including Diabetes and Diabetes Care; develops and updates the Standards of Medical Care in Diabetes; provides professional education and patient information; hosts scientific conferences; and advocates for policies that improve access to quality care. It collaborates with medical societies, academic institutions, and public agencies to advance science, clinical practice, and public health related to diabetes.
None yet. When a new project in the record names ADA as owner, partner or investor, it shows here.
Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.
FDA clears finerenone to reduce UACR in adults with CKD linked to type 1 diabetes, aiming to slow eGFR decline and lower risk of end‑stage kidney disease.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
Triple agonist produced up to 28.3% weight loss at 80 weeks, A1C fell up to 2.0% at 40 weeks, with large reductions in knee pain and sleep apnea severity.
Real‑world claims analysis found semaglutide 2 mg escalation gave similar HbA1c <7% rates and higher ≥5% weight‑loss rates than switching to titratable tirzepatide.
Post‑hoc analyses link semaglutide to lower OSA incidence, fewer asthma events, improved systolic BP, and liver and cardiometabolic improvements across SELECT, STEP, ESSENCE and OASIS trials.
Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.
